Yahoo Finance

AB Science provides an update on the application for conditional marketing authorisation of masitinib in ALS

AB SCIENCE PROVIDES AN UPDATE ON THE APPLICATION FOR CONDITIONAL MARKETING AUTHORISATION OF MASITINIB IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS AB Science SA (Euronext - FR0010557264 - AB) ...
The Manila Times

AB Science announces the initiation of coverage of its stock by Maxim Group with a target price of EUR 4.0 per share

AB Science SA (Euronext - FR0010557264 - AB) announces the initiation of coverage of its stock by Maxim Group, an independent US-based full-service investment bank, securities and wealth management ...
Yahoo Finance

AB Science will publish its 2024 annual financial report on May 9, 2025

AB Science SA (Euronext - FR0010557264 - AB) today announced that it has postponed the publication of its 2024 annual financial report, initially scheduled for 30 April 2025, to give the auditors time ...
Yahoo Finance

AB Science provides an update on the microtubule program AB8939 and in particular the ability of AB8939 to generate response on MECOM rearrangement

AB SCIENCE PROVIDES AN UPDATE ON THE MICROTUBULE PROGRAM AB8939 AND IN PARTICULAR THE ABILITY OF AB8939 TO GENERATE RESPONSE ON MECOM REARRANGEMENT AB Science SA (Euronext - FR0010557264 - AB) today ...
Taiwan News

AB Science announces a new publication on biorxiv that identifies AB8939 as a promising drug candidate for treating refractory acute myeloid leukemia and potentially other cancers

[1] Humbert M, Letard S, Goubard A, et al. Identification of AB8939, a novel synthetic microtubule destabilizer and ALDH inhibitor that overcomes multidrug resistance in tumor cells as a drug ...
The Manila Times

AB Science announces new publication on Medrxiv highlighting clinical benefit with masitinib in Amyotrophic Lateral Sclerosis patients prior any complete loss of function

AB SCIENCE ANNOUNCES NEW PUBLICATION ON MEDRXIV HIGHLIGHTING CLINICAL BENEFIT WITH MASITINIB IN AMYOTROPHIC LATERAL SCLEROSIS PATIENTS PRIOR ANY COMPLETE LOSS OF FUNCTION Significant improvement in ...
Finanznachrichten

AB Science announces that EMA granted orphan drug status to AB8939 for the treatment of acute myeloid leukemia

AB Science SA (Euronext - FR0010557264 - AB) announces today that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) granted orphan drug status to AB8939 for the ...
Business Insider

AB Science provides a summary of the webcast held on December 16, 2024

AB SCIENCE PROVIDES AN UPDATE ON AB8939, A NOVEL MICROTUBULE DESTABILIZER ESCAPING MULTIDRUG RESISTANCE AND STEM CELL TARGETED ALDH INHIBITOR, CURRENTLY IN PHASE 1 Paris, 17 December 2024, 7pm CET AB ...
Finanznachrichten

AB Science receives notice of allowance for Unites States patent covering masitinib until 2040 in the treatment of sickle cell disease

AB Science SA (Euronext - FR0010557264 - AB) today announced that the United States Patent Office has issued a Notice of Allowance for a patent relating to methods of treating sickle cell disease (i.e ...
Yahoo Finance

AB Science receives Chinese patent protecting masitinib in the treatment of Covid-19 until 2041, adding one more indication with long term intellectual property protection

AB SCIENCE RECEIVES CHINESE PATENT PROTECTING MASITINIB IN THE TREATMENT OF COVID-19 UNTIL 2041, ADDING ONE MORE INDICATION WITH LONG TERM INTELLECTUAL PROPERTY PROTECTION AB Science SA (Euronext - ...